BMS confirms Taisho’s $1.6bn offer for UPSAAfter protracted speculation, Bristol-Myers Squibb has confirmed it plans to divest its French over-the-counter (OTC) medicines business UPSA Share XBMS confirms Taisho’s $1.6bn offer for UPSAhttps://pharmaphorum.com/news/bms-confirms-taishos-1-6bn-offer-for-upsa/
